Obstructive sleep apnea syndrome
Conditions
Interventions
CPAP therapy will be initiated as a therapeutic intervention for obstructive sleep apnea accompanied by nocturia. After approximately four months of CPAP treatment, therapeutic efficacy will be evalua
Sponsors
Nara Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria Suspected OSA: Patients suspected of having OSA due to symptoms such as snoring, daytime sleepiness, or witnessed apneas, and who are deemed eligible for a diagnostic overnight polysomnography (PSG). Subjective symptoms of nocturia: Patients who report waking up one or more times to void between going to bed and waking up, within the past month. Age: 40 years of age or older. Sex: Any (however, sex differences will be accounted for in the analysis). Informed consent: Patients who have received a sufficient explanation regarding the purpose and contents of this study and have voluntarily provided written informed consent.
Exclusion criteria
Exclusion criteria: Exclusion Criteria Comorbidities affecting urine volume or voiding function: Poorly controlled diabetes mellitus (due to the effect of polyuria from osmotic diuresis). Severe heart failure (NYHA class III or higher) or chronic renal failure (as these constitute alternative causes of nocturnal polyuria). Active urinary tract infections (e.g., cystitis) or bladder cancer. Influence of medications: Patients currently taking diuretics, or those scheduled to initiate or change the dose of diuretics during the study period. Other conditions severely disrupting sleep: Patients with severe insomnia, restless legs syndrome (RLS), periodic limb movement disorder (PLMD), or similar conditions, in whom load sensor analysis is expected to be difficult due to excessive body movements. Physical limitations: Patients who have difficulty walking or transferring to the toilet independently (to exclude load changes caused by caregiver assistance). Patients whose body weight falls outside the measurable range of the sensor (e.g., under 40 kg or over 150 kg). Others: Patients deemed inappropriate for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concordance between the predicted and actual number of residual voiding events under CPAP therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Concordance of sleep stages and sleep efficiency between the load sensor and PSG | — |
Countries
Japan
Contacts
Public ContactRyosuke Kataoka
Nara Medical University Hospital Department of Respiratory Medicine
Outcome results
None listed